SLC5A2 and diabetic kidney disease: Cumulating evidence suggests that, besides the anti-hyperglycemic effect, SGLT2 inhibitors have a remarkable anti-inflammatory role in DKD (Ashrafi Jigheh et al., 2019; Hasan et al., 2020; Pirklbauer et al., 2020).